In conclusion, although questions remain for this challenging topic, the majority of studies tend to show that MHT displays rather a slight neutral or protective effect on colorectal adenoma and CRC risk and no effect on CRC mortality. Further research addressing potential mechanisms behind MHT effects on colon and rectum cancer development or investigating the possibility for a threshold duration necessary for protection and differences on the CRC effect by type of MHT would be helpful to elucidate the effect of MHT on CRC. Nevertheless, primary CRC prevention by MHT is currently not recommended by international guidelines due to several important harms such as higher risks for stroke, thromboembolic events, gallbladder disease and urine incontinence.
The authors are grateful for the support of DR. KADE/BESINS Pharma GmbH helping with ordering the identified publications.
Data Availability Statement
The data that support the findings of this study are openly available in the Open Science Framework by https://doi.org/10.17605/OSF.IO/FMBUZ.
Clin Endocrinol. 2021;95(3):390-397. © 2021 Blackwell Publishing